|
05 Aug 2022 |
Genmab and BioNTech Expand Global Strategic Collaboration to Develop and Commercialize Novel Immunotherapy Candidates
|
|
05 Aug 2022 |
Gilead Sciences to acquire MiroBio
|
|
05 Aug 2022 |
Amgen to acquire Chemocentryx for $4 billion in cash
|
|
04 Aug 2022 |
Radiopharm enters into strategic collaboration with Lantheus and assumes PD-L1 licensing agreement from Nanomab
|
|
03 Aug 2022 |
Rigel Pharmaceuticals and Forma Therapeutics Announce Licensing Agreement for Olutasidenib, a Novel Mutant IDH1 Inhibitor for the Potential Treatment of Relapsed or Refractory Acute Myeloid Leukemia
|
|
29 Jul 2022 |
Vicinitas Therapeutics Launches With $65 Million in Series A Financing to Advance Precision Medicines to Stabilize Key Proteins to Treat Disease
|
|
29 Jul 2022 |
Novartis and UC Berkeley Extend Alliance to Tackle 'Undruggable' Disease Targets and Discover New Therapeutic Modalities
|
|
25 Jul 2022 |
Rona Therapeutics Announces Exclusive Licensing Transaction from Sanofi for its Broad siRNA Therapeutic Portfolio and Technology Platform
|
|
21 Jul 2022 |
Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease
|
|
18 Jul 2022 |
Enterome signs major strategic R&D collaboration with Nestlé Health Science to develop and commercialize new AllerMimics™ and EndoMimics™ immunotherapies for food allergies and inflammatory bowel disease
|
|
13 Jul 2022 |
Orion and MSD announce global collaboration for the development and commercialisation of ODM-208, an investigational steroid synthesis inhibitor for the treatment of metastatic castration-resistant prostate cancer
|
|
13 Jul 2022 |
Heidelberg Pharma and Chiome Bioscience Sign Exclusive, Target-Specific Research and Option Agreement for the Development of an Antibody Drug Conjugate
|
|
12 Jul 2022 |
LegoChem Biosciences and Glycotope Announce Research Collaboration and License Agreement for an Antibody for use as Antibody Drug Conjugate
|
|
12 Jul 2022 |
Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes
|
|
07 Jul 2022 |
Exelixis and Ryvu Therapeutics Establish Exclusive License Agreement to Develop Novel STING Agonist-Based Targeted Cancer Therapies
|
|
06 Jul 2022 |
BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies
|
|
05 Jul 2022 |
Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets
|
|
05 Jul 2022 |
EditForce and Mitsubishi Tanabe Pharma Enter into License Agreement
|
|
05 Jul 2022 |
Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss
|
|
02 Jul 2022 |
Generian and Astellas Enter into Collaboration and Exclusive License Agreement to Discover and Develop Novel Small Molecules For Undruggable Targets
|
|
29 Jun 2022 |
Palleon Pharmaceuticals and Henlius Enter into Strategic Collaboration to Develop Bifunctional Sialidase Therapies
|
|
27 Jun 2022 |
Ipsen to acquire Epizyme, expanding its portfolio in oncology
|
|
24 Jun 2022 |
invoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs
|
|
23 Jun 2022 |
Alpha Tau Announces Treatment of First Prostate Cancer Patient with Alpha DaRT
|
|
22 Jun 2022 |
Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease
|
